HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Inclusion Criteria:

• Has a documented diagnosis of transthyretin (ATTR) amyloidosis with cardiomyopathy,classified as either hereditary ATTR (hATTR) amyloidosis with cardiomyopathy orwild-type ATTR (wtATTR) amyloidosis with cardiomyopathy meeting pre-specifieddiagnostic criteria

• Has medical history of heart failure (HF) with at least 1 prior hospitalization forHF OR clinical evidence of HF

Exclusion Criteria:

• Has known primary amyloidosis or leptomeningeal amyloidosis

• Has New York Heart Association (NYHA) Class IV heart failure

• Has NYHA Class III heart failure AND is at high risk based on pre-specified criteria

• Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV at the Screening visit

• Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2

• Has received prior TTR-lowering treatment

• Has other non-TTR cardiomyopathy, hypertensive cardiomyopathy, cardiomyopathy due tovalvular heart disease, or cardiomyopathy due to ischemic heart disease